-
Report Says Ocrevus is on the Rise for Newly Diagnosed Patients with MS
Spherix Global Insights’ 2nd annual report on MS medications and their use in the U.S. found that oral disease-modifying therapies are still in wide use among newly diagnosed patients but Ocrevus and generics are rising competitors.
Click here to find out more about this report!
What do you think about this news?
Sorry, there were no replies found.
Log in to reply.